155 related articles for article (PubMed ID: 12154278)
1. Aspirin therapy should be first line: probably, but watch this space.
Donnan GA; Davis SM
Stroke; 2002 Aug; 33(8):2139-40. PubMed ID: 12154278
[No Abstract] [Full Text] [Related]
2. Aspirin therapy should be first-line treatment in secondary prevention of stroke--against.
Diener HC
Stroke; 2002 Aug; 33(8):2138-9. PubMed ID: 12154277
[No Abstract] [Full Text] [Related]
3. Aspirin should be first-line antiplatelet therapy in the secondary prevention of stroke.
Warlow C
Stroke; 2002 Aug; 33(8):2137-8. PubMed ID: 12154276
[No Abstract] [Full Text] [Related]
4. [Treatment of ischemic heart disease with the platelet aggregation inhibitor clopidogrel].
Helø OH; Madsen JK; Kastrup J
Ugeskr Laeger; 2004 Apr; 166(18):1659-62. PubMed ID: 15174400
[No Abstract] [Full Text] [Related]
5. Newer antiplatelet therapies in stroke prevention.
Davis SM; Donnan GA
Aust Fam Physician; 2001 Feb; 30(2):129-34. PubMed ID: 11280112
[TBL] [Abstract][Full Text] [Related]
6. Update to the AHA/ASA recommendations for the prevention of stroke in patients with stroke and transient ischemic attack.
Adams RJ; Albers G; Alberts MJ; Benavente O; Furie K; Goldstein LB; Gorelick P; Halperin J; Harbaugh R; Johnston SC; Katzan I; Kelly-Hayes M; Kenton EJ; Marks M; Sacco RL; Schwamm LH; ;
Stroke; 2008 May; 39(5):1647-52. PubMed ID: 18322260
[No Abstract] [Full Text] [Related]
7. What is the best antiplatelet agent for prevention of recurrent stroke in Pakistani patients? Do combinations offer significant advantages in the South Asian context?
Khan M; Kamal AK
J Pak Med Assoc; 2010 Sep; 60(9):783-4. PubMed ID: 21381596
[No Abstract] [Full Text] [Related]
8. Secondary stroke prevention set to benefit from PRoFESS trial: extended-release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit-risk ratio in vascular prevention.
Cardiovasc J Afr; 2008; 19(3):165. PubMed ID: 18568182
[No Abstract] [Full Text] [Related]
9. Antiplatelet therapy: a neurology perspective.
Brass LM
Manag Care; 2000 Oct; 9(10 Suppl):13-5. PubMed ID: 11729420
[No Abstract] [Full Text] [Related]
10. Antiplatelet therapy: a neurology perspective.
Brass LM
Manag Care; 2000 May; 9(5 Suppl):15-7. PubMed ID: 11729408
[No Abstract] [Full Text] [Related]
11. Antiplatelets in secondary stroke prevention: should clopidogrel be the first choice?
Aw D; Sharma JC
Postgrad Med J; 2012 Jan; 88(1035):34-7. PubMed ID: 22121248
[TBL] [Abstract][Full Text] [Related]
12. Antiplatelet therapy to prevent recurrent stroke: Three good options.
Mansoor AH; Mujtaba MT; Silver B
Cleve Clin J Med; 2013 Dec; 80(12):787-95. PubMed ID: 24307163
[TBL] [Abstract][Full Text] [Related]
13. Combination antiplatelet agents for secondary prevention of ischemic stroke.
Vande Griend JP; Saseen JJ
Pharmacotherapy; 2008 Oct; 28(10):1233-42. PubMed ID: 18823219
[TBL] [Abstract][Full Text] [Related]
14. [Secondary prevention with clopidogrel after TIA or stroke].
Zuurbier SM; Vermeer SE; Hilkens PH; Algra A; Roos YB
Ned Tijdschr Geneeskd; 2013; 157(25):A5836. PubMed ID: 23777963
[TBL] [Abstract][Full Text] [Related]
15. Trends in usage of alternative antiplatelet therapy after stroke and transient ischemic attack.
Hills NK; Johnston SC
Stroke; 2008 Apr; 39(4):1228-32. PubMed ID: 18323509
[TBL] [Abstract][Full Text] [Related]
16. Clopidogrel plus aspirin for stroke prevention.
Alberts MJ; Easton JD
Stroke; 2002 Nov; 33(11):2546-7; author reply 2546-7. PubMed ID: 12411639
[No Abstract] [Full Text] [Related]
17. Antiplatelet therapy.
Nicholls C; Sani M
Nurs Older People; 2004 Nov; 16(8):35-6. PubMed ID: 15552503
[No Abstract] [Full Text] [Related]
18. [Antithrombotic treatment as primary and secondary prevention of stroke].
Chukanova EI; Chukanova AS; Nadareyshvili GG; Gulieva MS
Zh Nevrol Psikhiatr Im S S Korsakova; 2016; 116(10):85-88. PubMed ID: 28635860
[TBL] [Abstract][Full Text] [Related]
19. Effect of combined aspirin and extended-release dipyridamole versus clopidogrel on functional outcome and recurrence in acute, mild ischemic stroke: PRoFESS subgroup analysis.
Bath PM; Cotton D; Martin RH; Palesch Y; Yusuf S; Sacco R; Diener HC; Estol C; Roberts R;
Stroke; 2010 Apr; 41(4):732-8. PubMed ID: 20181679
[TBL] [Abstract][Full Text] [Related]
20. Counting the true cost of antiplatelet therapy for stroke prevention.
Morton JA; Newton J; Gray CS
Age Ageing; 2005 May; 34(3):212-4. PubMed ID: 15863405
[No Abstract] [Full Text] [Related]
[Next] [New Search]
